This page shows the latest American Heart Association meeting news and features for those working in and with pharma, biotech and healthcare.
Novartis isn’t commenting on the speculation, but Bloomberg analyst Sam Fazeli says that inclisiran would slot neatly into the Swiss group’s cardiovascular portfolio alongside Entresto (sacubitril/valsartan), its heart ... At the American Heart
The ORION-9 and ORION-10 data will be reported in full at the American Heart Association (AHA) meeting in November.
The product has new cardiovascular outcomes data from the DECLARE-TIMI 58 trial – a must-have for diabetes therapies now – which is due for presentation at the American Heart Association (AHA) ... It will be followed by additional studies in patients
At the American Heart Association (AHA) annual meeting this week, lead study author Stephen Nichols of the University of Adelaide in Australia reported that adding a monthly Repatha shot to daily ... The results have also been published in the Journal of
These include cholesterol-lowering antibody alirocumab (now given the proposed trade name of Praluent) - fresh from encouraging new data presented at the American Heart Association meeting - as well a vaccine against ... the company will be keen to
Sanofi and Regeneron’s drug impresses at American Heart Association meeting. Sanofi and Regeneron's investigational drug alirocumab is more effective at reducing cholesterol levels than Merck &Co's Zetia in ... The ODYSSEY ALTERNATIVE trial - reported
More from news
Approximately 1 fully matching, plus 12 partially matching documents found.
M3 has over 20 years’ experience in building online doctor communities. M3 is the world’s largest network of verified doctors...